ATE445410T1 - Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie - Google Patents

Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie

Info

Publication number: ATE445410T1
Authority: AT; Austria
Prior art keywords: growth; neoplasia; combinations; treatment; hormones
Prior art date: 2002-12-27

Application number

AT03767380T

Other languages

English (en)

Inventor

Fuentes Eddy Bover

Baker R Basulto

Vazquez Eulogio Pimentel

Barranco Jesus Junco

Aguilar Franklin Fuentes

More Niurka Arteaga

Aguilera Lesvia Calzada

Dominguez Hector Hernandez

Saez Yovisleidys Lopez

Nieto Gerardo Guillen

Santiago Glay Chinea

Original Assignee

Ct Ingenieria Genetica Biotech

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-27

Filing date

2003-12-22

Publication date

2009-10-15

2003-12-22 Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech

2009-10-15 Application granted granted Critical

2009-10-15 Publication of ATE445410T1 publication Critical patent/ATE445410T1/de

Links

229940088597 hormone Drugs 0.000 title abstract 4
239000005556 hormone Substances 0.000 title abstract 3
206010028980 Neoplasm Diseases 0.000 title abstract 2
230000012010 growth Effects 0.000 title abstract 2
230000009826 neoplastic cell growth Effects 0.000 title 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 abstract 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
230000006023 anti-tumor response Effects 0.000 abstract 1
239000003102 growth factor Substances 0.000 abstract 1
239000000122 growth hormone Substances 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
230000001568 sexual effect Effects 0.000 abstract 1
230000004083 survival effect Effects 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001131—Epidermal growth factor [EGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001134—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00113—Growth factors
- A61K39/001135—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Mycology (AREA)
Oncology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Steroid Compounds (AREA)
Silicon Compounds (AREA)

AT03767380T 2002-12-27 2003-12-22 Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie ATE445410T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CU20020338A CU23204A1 (es)	2002-12-27	2002-12-27	Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
PCT/CU2003/000019 WO2004058297A1 (es)	2002-12-27	2003-12-22	Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Publications (1)

Publication Number	Publication Date
ATE445410T1 true ATE445410T1 (de)	2009-10-15

Family

ID=40091671

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03767380T ATE445410T1 (de)	2002-12-27	2003-12-22	Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie

Country Status (17)

Country	Link
US (1)	US20060193853A1 (de)
EP (1)	EP1576965B1 (de)
JP (1)	JP4384054B2 (de)
KR (1)	KR100712426B1 (de)
CN (1)	CN1732017B (de)
AT (1)	ATE445410T1 (de)
AU (1)	AU2003291915B2 (de)
BR (1)	BR0317506A (de)
CA (1)	CA2507470C (de)
CU (1)	CU23204A1 (de)
DE (1)	DE60329710D1 (de)
ES (1)	ES2334344T3 (de)
MX (1)	MXPA05006979A (de)
MY (1)	MY140305A (de)
RU (1)	RU2321422C2 (de)
WO (1)	WO2004058297A1 (de)
ZA (1)	ZA200504820B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8163283B2 (en) *	2009-09-03	2012-04-24	Vancouver Biotech Ltd.	Monoclonal antibodies against gonadotropin-releasing hormone receptor
CA2800488A1 (en) *	2010-05-26	2011-12-01	Regents Of The University Of Minnesota	Single-chain variable fragment anti-cd133 antibodies and uses thereof
CN104004762B (zh) *	2014-05-20	2016-03-30	南京医科大学附属南京儿童医院	Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用
JP2020505379A (ja) *	2017-01-20	2020-02-20	イミューンシステムレギュレェイションホールディングエービー	新規化合物（イムノレリン）
SG11201911430PA (en)	2017-07-04	2020-01-30	Curevac Ag	Novel nucleic acid molecules
JP7677953B2 (ja) *	2019-09-12	2025-05-15	ヘキサマー・セラピューティクス・インコーポレイテッド	前立腺癌処置のための免疫治療薬
WO2025088088A1 (en)	2023-10-27	2025-05-01	CureVac SE	Rna composition for improving cell therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2228262B (en) *	1989-01-25	1992-10-07	Nat Inst Immunology	Antigenic derivative of gnrh
US5211952A (en) *	1991-04-12	1993-05-18	University Of Southern California	Contraceptive methods and formulations for use therein
AU687727B2 (en) *	1992-10-28	1998-03-05	Genentech Inc.	Vascular endothelial cell growth factor antagonists
CA2261433A1 (en) *	1993-12-09	1995-06-10	Belinda Sanchez Ramirez	Composition comprising autologous epidermal growth factor
CU22627A1 (es) *	1996-12-17	2000-12-22	Ct Ingenieria Genetica Biotech	Preparado vacunal para la inmuno-castración reversible de mamíferos
CU23077A1 (es) *	2000-12-06	2005-08-17	Centro Inmunologia Molecular	Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
US8026229B2 (en) *	2001-08-13	2011-09-27	Sterix Limited	Antitumor-active 2-alkoxyestradiol sulfamates

2002
- 2002-12-27 CU CU20020338A patent/CU23204A1/es not_active IP Right Cessation
2003
- 2003-12-22 US US10/539,172 patent/US20060193853A1/en not_active Abandoned
- 2003-12-22 CA CA2507470A patent/CA2507470C/en not_active Expired - Fee Related
- 2003-12-22 RU RU2005123813/13A patent/RU2321422C2/ru not_active IP Right Cessation
- 2003-12-22 KR KR1020057009823A patent/KR100712426B1/ko not_active Expired - Fee Related
- 2003-12-22 CN CN2003801075594A patent/CN1732017B/zh not_active Expired - Fee Related
- 2003-12-22 JP JP2004562478A patent/JP4384054B2/ja not_active Expired - Fee Related
- 2003-12-22 ES ES03767380T patent/ES2334344T3/es not_active Expired - Lifetime
- 2003-12-22 AT AT03767380T patent/ATE445410T1/de active
- 2003-12-22 MX MXPA05006979A patent/MXPA05006979A/es active IP Right Grant
- 2003-12-22 AU AU2003291915A patent/AU2003291915B2/en not_active Ceased
- 2003-12-22 WO PCT/CU2003/000019 patent/WO2004058297A1/es not_active Ceased
- 2003-12-22 BR BR0317506-5A patent/BR0317506A/pt not_active IP Right Cessation
- 2003-12-22 DE DE60329710T patent/DE60329710D1/de not_active Expired - Lifetime
- 2003-12-22 EP EP03767380A patent/EP1576965B1/de not_active Expired - Lifetime
- 2003-12-24 MY MYPI20034978A patent/MY140305A/en unknown
2006
- 2006-01-16 ZA ZA200504820A patent/ZA200504820B/en unknown

Also Published As

Publication number	Publication date
ES2334344T3 (es)	2010-03-09
CN1732017B (zh)	2011-12-21
CA2507470A1 (en)	2004-07-15
RU2321422C2 (ru)	2008-04-10
EP1576965A1 (de)	2005-09-21
RU2005123813A (ru)	2006-01-27
ZA200504820B (en)	2006-03-29
CN1732017A (zh)	2006-02-08
WO2004058297A1 (es)	2004-07-15
DE60329710D1 (de)	2009-11-26
CA2507470C (en)	2010-11-09
AU2003291915A1 (en)	2004-07-22
EP1576965B1 (de)	2009-10-14
AU2003291915B2 (en)	2008-12-04
KR100712426B1 (ko)	2007-04-27
JP2006514036A (ja)	2006-04-27
CU23204A1 (es)	2007-05-18
MY140305A (en)	2009-12-31
KR20050089016A (ko)	2005-09-07
BR0317506A (pt)	2005-11-16
MXPA05006979A (es)	2005-08-16
US20060193853A1 (en)	2006-08-31
JP4384054B2 (ja)	2009-12-16

Legal Events

Date

Code

Title

Description

2010-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1576965

Country of ref document: EP

Publication	Publication Date	Title
NZ774980A (en)	2024-11-29	Trem2 stabilizing antibodies
MX2022010425A (es)	2022-09-07	Metodos de tratamiento de enfermedades asociadas a los receptores de estrogenos.
ATE445410T1 (de)	2009-10-15	Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie
WO2020014460A8 (en)	2020-02-13	HIGH-AFFINITY, ISOFORM-SELECTIVE TGFβ1 INHIBITORS AND USE THEREOF
PL356846A1 (en)	2004-07-12	Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
PL351125A1 (en)	2003-03-24	Derivatives of 4,5-diaryl-3(2)-furanone as inhibitors of cykoxygenease-2
MX2022006073A (es)	2022-08-04	Metodos para utilizar anticuerpos anti-trem2.
ATE288444T1 (de)	2005-02-15	Dipeptide, die die ausschüttung von wachstumshormonen stimulieren
MXPA05013824A (es)	2006-02-28	Inhibidores de quinasa p38 basados en heterociclos de 5 miembros.
JO2481B1 (en)	2009-01-20	Silo cano-indol compounds have fluoride substitution and formulations containing such compounds and their treatment methods
WO2003105732A8 (fr)	2005-03-03	Systeme pour le traitement de l'obesite et implant pour un tel systeme
TW200621804A (en)	2006-07-01	Ctla-4 antibody and aromatase inhibitor combination treatment for breast cancer
JOP20220071A1 (ar)	2022-03-17	سيتوكين مناعي يشمل معقد بروتين دايمري غير متجانس على أساس IL-15/IL-15Ra
MX2021007948A (es)	2021-08-11	Inhibidores de proteina de activacion de fibroblastos.
MXPA04002256A (es)	2004-07-23	Uso de gonadotropina corionica humana (gch) en hiperestimulacion ovarica controlada.
NO20075764L (no)	2008-01-14	Kombinert anvendelse av prostaglandinforbindelse og protonpumpeinhibitor til behandling av forstyrrelser i mage- og tarmkanalen
NZ762312A (en)	2022-11-25	Anti-pacap antibody
MX2025004473A (es)	2025-06-02	Novedosos anticuerpos anti-napi2b y conjugados-anticuerpo-droga basados en ellos, metodos terapeuticos y usos de los mismos
MX2024002069A (es)	2024-03-15	Anticuerpos anti-hla-g.
EA200600936A1 (ru)	2006-10-27	Способы регуляции фактора некроза опухоли альфа
AU2002357644A8 (en)	2004-04-08	Therapeutic agents and corresponding treatments
MXPA04002257A (es)	2004-07-23	Uso de gonadotropina corionica humana (gch) y su hormona de liberacion (hl) en hiperestimulacion ovarica controlada.
MX2018009352A (es)	2018-09-05	Metodos y composiciones para controlar hormigas.
CN111836428B (zh)	2024-08-02	具有低待机功率的pwm调光电路
PH12021550417A1 (en)	2021-09-20	Compositions and methods for controlled ovarian stimulation